Tiziana Life Sciences Showcases Breakthrough in Alzheimer’s Treatment with Intranasal Foralumab

An update from Tiziana Life Sciences ( (TLSA) ) is now available.

On May 23, 2025, Tiziana Life Sciences announced advancements in the treatment of moderate Alzheimer’s disease through their novel nasal spray, foralumab. Featured in a national public radio interview, Dr. Howard Weiner shared promising results from the first patient treated, Joe Walsh, who experienced significant improvements at Brigham and Women’s Hospital in Boston. This development marks a significant step forward in Alzheimer’s research, as intranasal foralumab targets immune cells in the brain to reduce inflammation, a key factor in the disease’s progression.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to improve efficacy and safety compared to traditional intravenous delivery methods. The company is committed to advancing immunotherapy through alternative routes, with a patented technology that supports a broad range of applications.

Average Trading Volume: 722,875

Technical Sentiment Signal: Buy

Current Market Cap: $152.7M

See more insights into TLSA stock on TipRanks’ Stock Analysis page.